Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Low Socioeconomic Status Confers Poorer Real-World Overall Survival for Patients with Acute Myeloid Leukemia Treated in the Modern Era

Mark A Guinter, Brendan T Kerr, Gregory S Calip, Anita J Kumar, Ahmed Sawas

Blood (2023) 142 (Supplement 1): 2437.

https://doi.org/10.1182/blood-2023-186137

Published: 2023

Journal Articles

Understanding Treatment Decisions for Hodgkin Lymphoma: A Qualitative Study

Laurie K Pearson, Anita J Kumar, John B Wong, Jonathan W. Friedberg, Amy LeClair, Susan K. Parsons

Blood (2022) 140 (Supplement 1): 7917–7918.

https://doi.org/10.1182/blood-2022-156496

Published: 2022

Journal Articles

Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL)

Anita J Kumar, MDMS, Jason Nelson, MPH, Angie Mae Rodday, PhD, Andrew M. Evens, DO,MMSc, Jonathan W. Friedberg, MD MSSc, Tanya M. Wildes, MD MSCI, Susan K Parsons, MD MRP

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140823

Published: 2020

Journal Articles

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Anita J Kumar, MDMS, Rachel Murphy-Banks, MA, Ruth Ann Weidner, MBA, MRP, Susan K Parsons, MD MRP

Blood (2019) 134 (Supplement_1): 2137.

https://doi.org/10.1182/blood-2019-124481

Published: 2019

Journal Articles

Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens

Angie Mae Rodday, PhD, Theresa E. Hahn, PhD, Anita J Kumar, MDMS, Peter K Lindenauer, MD MSc, Jonathan W. Friedberg, MD, Andrew Matthew Evens, DO,MMSc, Susan K Parsons, MD MRP

Blood (2019) 134 (Supplement_1): 1563.

https://doi.org/10.1182/blood-2019-124141

Published: 2019

Journal Articles

Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis of Statewide Claims Data

Anem Waheed, MD MPH, Angie Mae Rodday, PhD MS, Anita J Kumar, MD MS, Kenneth B. Miller, MD, Susan K Parsons, MD MRP

Blood (2018) 132 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2018-99-111921

Published: 2018

Journal Articles

Higher Socioeconomic Status Is Associated with Improved Overall Survival in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: A Population Study

Anita J Kumar, MD MS, Tobi Henzer, BS, Angie Mae Rodday, PhD MS, Marlise R. Luskin, MD, Wendy Stock, MD, Susan K Parsons, MD MRP

Blood (2018) 132 (Supplement 1): 4780.

https://doi.org/10.1182/blood-2018-99-114773

Published: 2018

Journal Articles

The Development and Validation of an Electronic Health Record (EHR)-Based Algorithm for Identifying Treatment Failure in Newly Diagnosed Hodgkin Lymphoma (HL) Treated in a US Community Oncology Setting

Chun R Chao, PhD, Lanfang Xu, Nancy Cannizzaro, PhD, Angie Mae Rodday, PhD MS, Joseph Feliciano, PharmD, Anita J Kumar, MD MS, Andrew M. Evens, DO, MSc, Susan K Parsons, MD MRP

Blood (2018) 132 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2018-99-112225

Published: 2018

Journal Articles

Drawing the line of ineligibility

Anita J. Kumar

Blood (2018) 131 (25): 2739–2740.

https://doi.org/10.1182/blood-2018-04-844704

Published: 2018

Journal Articles

Longer Length of Stay and No Chemotherapy Is Associated with Greater Likelihood of Death during Hospitalization in Patients with Diffuse Large B-Cell Lymphoma: An Analysis from the National Inpatient Sample (NIS)

Anita J. Kumar, MD, Tobi Henzer, Angie Mae Rodday, PhDMS, Susan K Parsons, MD MRP

Blood (2017) 130 (Supplement 1): 2121.

https://doi.org/10.1182/blood.V130.Suppl_1.2121.2121

Published: 2017

Journal Articles

The Incidence and Cost of Hospice Use Among Elderly Patients with Diffuse Large B-Cell Lymphoma: A SEER-Medicare Analysis

Anita J Kumar, MD MS, Aaron Winn, MPP, Gunjan L Shah, MD MS, Pei-Jung Lin, PhD MS, Susan K Parsons, MD MRP

Blood (2016) 128 (22): 5951.

https://doi.org/10.1182/blood.V128.22.5951.5951

Published: 2016

Journal Articles

Comparison of Survival and Costs of Rituximab-Based Chemotherapy for Initial Therapy of Follicular Lymphoma in Elderly Patients

Gunjan L. Shah, MDMS, Aaron Winn, MPP, Pei-Jung Lin, PhDMS, Anita J Kumar, MDMS, Susan K Parsons, MDMRP

Blood (2016) 128 (22): 2354.

https://doi.org/10.1182/blood.V128.22.2354.2354

Published: 2016

Journal Articles

Patient and Hospital Characteristics Associated with Increased Length of Stay for Patients with Acute Myeloid Leukemia (AML): An Analysis from the 2012 National Inpatient Sample (NIS)

Anita J Kumar, MDMS, Toby Henzer, Angie Mae Rodday, PhDMS, Susan K Parsons, MDMRP

Blood (2016) 128 (22): 3572.

https://doi.org/10.1182/blood.V128.22.3572.3572

Published: 2016

Journal Articles

Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes

Anita J Kumar, MDMS, Soyoung Kim, PhD, Michael Hemmer, MS, Mukta Arora, MD, Steve Spellman, MBS, Joseph A. Pidala, MD, Daniel Couriel, MD MS, Amin M. Alousi, MD, Alison W Loren, MD MS

Blood (2016) 128 (22): 70.

https://doi.org/10.1182/blood.V128.22.70.70

Published: 2016

Journal Articles

The Utility of the Charlson Comorbidity Index in Predicting Use of Treatment and Survival in Older Lymphoma Patients

Gunjan L. Shah, MD MS, Aaron Winn, MPP, Anita J Kumar, MD MS, Miguel-Angel Perales, MD, Pei-Jung Lin, Ph DMS, Susan K Parsons, MD MRP

Blood (2016) 128 (22): 2405.

https://doi.org/10.1182/blood.V128.22.2405.2405

Published: 2016

Journal Articles

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Noelle V. Frey, MDMS, Selina Luger, MD, James Mangan, MD PhD, Alexis Zebrowski, BA, Alison W. Loren, MDMS, Hans Minderman, John Baird, MD, David L Porter, MD, Elizabeth O. Hexner, MD, Anita J. Kumar, MDMS, Marlise R. Luskin, MD, Alexander E Perl, MD, Martin Carroll, MD

Blood (2014) 124 (21): 3758.

https://doi.org/10.1182/blood.V124.21.3758.3758

Published: 2014

Journal Articles

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Jingmei Hsu, MD PhD, Anita J. Kumar, MDMS, Martin P. Carroll, MD, Noelle V. Frey, MDMS, Nirav N. Shah, MD, Zhao Jianhua, PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, James K. Mangan, MDPhD, Alexander E. Perl, MD, David Porter, MD, Jennifer Morrissette, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2343.

https://doi.org/10.1182/blood.V124.21.2343.2343

Published: 2014

Journal Articles

Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT)

Anita J. Kumar, MDMS, Phyllis A. Gimotty, PhD, Joel Gelfand, MDMS, Georgina Buck, Jacob M. Rowe, MD, Anthony H Goldstone, MD, Adele Fielding, MB BS, PhD, David I Marks, Mark Litzow, Elisabeth Paietta, PhD, Hillard M. Lazarus, Martin S. Tallman, MD, Selina M. Luger, MD, Alison W. Loren, MDMS

Blood (2014) 124 (21): 208.

https://doi.org/10.1182/blood.V124.21.208.208

Published: 2014

Journal Articles

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Anita J. Kumar, MDMS, Pavel Vassilev, BS, Alison W. Loren, MDMS, Selina M. Luger, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Steven C. Goldstein, MD, Elizabeth Hexner, MD, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 3946.

https://doi.org/10.1182/blood.V124.21.3946.3946

Published: 2014

Journal Articles

Inhibition of the Renin Angiotensin System During Autologous Stem Cell Transplant Does Not Impact Time to Engraftment □s€

Anita J. Kumar, MD, Joseph R Carver, MD, Noelle V. Frey, MD

Blood (2012) 120 (21): 4502.

https://doi.org/10.1182/blood.V120.21.4502.4502

Published: 2012

NARROW

Low Socioeconomic Status Confers Poorer Real-World Overall Survival for Patients with Acute Myeloid Leukemia Treated in the Modern Era

Understanding Treatment Decisions for Hodgkin Lymphoma: A Qualitative Study

Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL)

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens

Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis of Statewide Claims Data

Higher Socioeconomic Status Is Associated with Improved Overall Survival in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: A Population Study

The Development and Validation of an Electronic Health Record (EHR)-Based Algorithm for Identifying Treatment Failure in Newly Diagnosed Hodgkin Lymphoma (HL) Treated in a US Community Oncology Setting

Drawing the line of ineligibility

Longer Length of Stay and No Chemotherapy Is Associated with Greater Likelihood of Death during Hospitalization in Patients with Diffuse Large B-Cell Lymphoma: An Analysis from the National Inpatient Sample (NIS)

The Incidence and Cost of Hospice Use Among Elderly Patients with Diffuse Large B-Cell Lymphoma: A SEER-Medicare Analysis

Comparison of Survival and Costs of Rituximab-Based Chemotherapy for Initial Therapy of Follicular Lymphoma in Elderly Patients

Patient and Hospital Characteristics Associated with Increased Length of Stay for Patients with Acute Myeloid Leukemia (AML): An Analysis from the 2012 National Inpatient Sample (NIS)

Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes

The Utility of the Charlson Comorbidity Index in Predicting Use of Treatment and Survival in Older Lymphoma Patients

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT)

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Inhibition of the Renin Angiotensin System During Autologous Stem Cell Transplant Does Not Impact Time to Engraftment □s€

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only